Literature DB >> 10868072

The impact of prior authorization on outpatient utilization in managed behavioral health plans.

X Liu, R Sturm, B J Cuffel.   

Abstract

This study examines how preauthorization affects outpatient behavioral health utilization under managed care by comparing plans with similar benefits, but differing in the number of visits authorized. The authors compare plans primarily authorizing in increments of 5 visits to plans authorizing in increments of 10 visits. They analyze the likelihood of terminating outpatient service between the two groups using conditional logistic regression. Results suggest that patients whose treatment is authorized in increments of 5 sessions are nearly 3 times more likely to terminate treatment at exactly the fifth visit than if their treatment is authorized in increments of 10 sessions conditional on being in treatment until the 5th visit. The likelihood of termination peaks in both the 5- and 10-session authorization at the 10th visit, but the difference is not statistically significant. The authorization effect differs by provider type and is weaker among psychiatrists than among nonphysician providers.

Entities:  

Mesh:

Year:  2000        PMID: 10868072     DOI: 10.1177/107755870005700203

Source DB:  PubMed          Journal:  Med Care Res Rev        ISSN: 1077-5587            Impact factor:   3.929


  12 in total

1.  Changes in managed care activity in outpatient substance abuse treatment organizations, 1995-2000.

Authors:  Jeffrey A Alexander; Christy Harris Lemak; Cynthia I Campbell
Journal:  J Behav Health Serv Res       Date:  2003 Oct-Dec       Impact factor: 1.505

2.  The administrative control system of substance abuse managed care.

Authors:  Michael R Sosin
Journal:  Health Serv Res       Date:  2005-02       Impact factor: 3.402

3.  Changes in how health plans provide behavioral health services.

Authors:  Constance M Horgan; Deborah W Garnick; Elizabeth Levy Merrick; Dominic Hodgkin
Journal:  J Behav Health Serv Res       Date:  2007-09-14       Impact factor: 1.505

4.  Does type of gatekeeping model affect access to outpatient specialty mental health services?

Authors:  Dominic Hodgkin; Elizabeth L Merrick; Constance M Horgan; Deborah W Garnick; Thomas J McLaughlin
Journal:  Health Serv Res       Date:  2007-02       Impact factor: 3.402

5.  EMPLOYER CHOICES IN EAP DESIGN AND WORKSITE SERVICES.

Authors:  Bernard McCann; Vanessa Azzone; Elizabeth L Merrick; Deirdre Hiatt; Dominic Hodgkin; Constance M Horgan
Journal:  J Workplace Behav Health       Date:  2010

6.  The sensitivity of substance abuse treatment intensity to co-payment levels.

Authors:  Anthony T Lo Sasso; John S Lyons
Journal:  J Behav Health Serv Res       Date:  2004 Jan-Mar       Impact factor: 1.505

7.  A "community-friendly" version of integrated group therapy for patients with bipolar disorder and substance dependence: a randomized controlled trial.

Authors:  Roger D Weiss; Margaret L Griffin; William B Jaffee; Rachel E Bender; Fiona S Graff; Robert J Gallop; Garrett M Fitzmaurice
Journal:  Drug Alcohol Depend       Date:  2009-07-01       Impact factor: 4.492

8.  Medical Costs of Persons with Drug Use Disorders Among Medicaid Managed Care Beneficiaries in Puerto Rico : Comparison of the Direct Services Costs Incurred by Beneficiaries With and Without a Drug Use Disorder.

Authors:  Héctor M Colón Jordán; José E Laborde Rivera; Heriberto A Marín Centeno; Carmen E Albizu-García
Journal:  J Behav Health Serv Res       Date:  2016-04       Impact factor: 1.505

9.  Accessing specialty behavioral health treatment in private health plans.

Authors:  Elizabeth L Merrick; Constance M Horgan; Deborah W Garnick; Sharon Reif; Maureen T Stewart
Journal:  J Behav Health Serv Res       Date:  2008-12-23       Impact factor: 1.505

10.  Changing mental health gatekeeping: effects on performance indicators.

Authors:  Elizabeth Levy Merrick; Dominic Hodgkin; Constance M Horgan; Deborah W Garnick; Thomas J McLaughlin
Journal:  J Behav Health Serv Res       Date:  2007-07-27       Impact factor: 1.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.